Effect of GnT-V knockdown on the proliferation, migration and invasion of the SMMC7721/R human hepatocellular carcinoma drug-resistant cell line

Li,Bo; Su,Song; Zhang,Meng‑Yu; He,Lei; Wang,Qing‑Da; He,Kai

doi:10.3892/mmr.2015.4492

Effect of GnT-V knockdown on the proliferation, migration and invasion of the SMMC7721/R human hepatocellular carcinoma drug-resistant cell line

Authors:
- Bo Li
- Song Su
- Meng‑Yu Zhang
- Lei He
- Qing‑Da Wang
- Kai He
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, The Affiliated Hospital of Sichuan Medical University, Luzhou, Sichuan 646000, P.R. China
Published online on: October 29, 2015 https://doi.org/10.3892/mmr.2015.4492
Pages: 469-476

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is a commonly occurring malignant tumor, with a high incidence rate. The present study aimed to investigate the effect of knocking down the N‑glycosyltransferase‑V (GnT‑V) protein on the proliferation, migration and invasion of the human HCC drug‑resistant cell line, SMMC7721/R. SMMC7721/R cells with GnT‑V‑knockdown (SMMC‑7721/R‑GnT‑V) were constructed using the method of lentiviral transfection. The expression of GnT‑V was assessed using reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blotting. Cell proliferation was determined using an MTT assay, and the extent of cellular apoptosis was assessed using flow cytometric analysis. Additionally, the metastatic ability of the cells in vitro was analyzed using cell adhesion and invasion assays. Western blotting was used to investigate the protein expression levels of caspase‑3, caspase‑9, Bcl‑2, Bax, matrix metalloproteinase (MMP)‑2 and MMP‑9, and RT‑qPCR was used to determine the mRNA expression levels of the genes for the breast cancer resistance protein and P‑glycoprotein in the SMMC‑7721/R cells. Taken together, the results of the present study revealed that the knockdown of GnT‑V significantly suppressed the proliferation, migration and invasion (P<0.05) of the SMMC‑7721/R cells. Furthermore, the possible mechanism underlying these phenomena may be associated with the induction of mitochondria‑mediated apoptosis, inhibition of the degradation of the extracellular matrix and an enhancement of the drug-sensitivity. GnT‑V‑knockdown may therefore be used to treat drug‑resistant HCC in the future.

View Figures

View References

1	Lafaro KJ, Demirjian AN and Pawlik TM: Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 24:1–17. 2015. View Article : Google Scholar
2	Stewart BW and Wild CP: World Cancer Report 2014. IARC; Nonserial Publication: 2014
3	Nordenstedt H, White DL and El-Serag HB: The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 42(Suppl 3): S206–S214. 2010. View Article : Google Scholar : PubMed/NCBI
4	El-Serag HB and Kanwal F: Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go? Hepatology. 60:1767–1775. 2014. View Article : Google Scholar : PubMed/NCBI
5	Kew MC and Kew MC: Hepatocellular carcinoma: Epidemiology and risk factors. J Hepa Carc. 1:115–125. 2014.
6	Chakraborty AK and Pawelek JM: GnT-V, macrophage and cancer metastasis: A common link. Clin Exp Metastasis. 20:365–373. 2003. View Article : Google Scholar : PubMed/NCBI
7	Song K, Ko JH and Kim YS: Role of N-acetylglucosaminyltra nsferase-V and galectin-3 binding protein in anoikis stress of cancer cells (788.1). FASEB J. 28:781–788. 2014.
8	Murata K, Miyoshi E, Kameyama M, Ishikawa O, Kabuto T, Sasaki Y, Hiratsuka M, Ohigashi H, Ishiguro S, Ito S, et al: Expression of N-acetylglucosaminyltransferase V in colorectal cancer correlates with metastasis and poor prognosis. Clin Cancer Res. 6:1772–1777. 2000.PubMed/NCBI
9	Handerson T, Camp R, Harigopal M, Rimm D and Pawelek J: β1, 6-branched oligosaccharides are increased in lymph node metastases and predict poor outcome in breast carcinoma. Clin Cancer Res. 11:2969–2973. 2005. View Article : Google Scholar : PubMed/NCBI
10	Takahashi N, Yamamoto E, Ino K, Miyoshi E, Nagasaka T, Kajiyama H, Shibata K, Nawa A and Kikkawa F: High expression of N-acetylglucosaminyltransferase V in mucinous tumors of the ovary. Oncol Rep. 22:1027–1032. 2009.PubMed/NCBI
11	Huang B, Sun L, Cao J, Zhang Y, Wu Q, Zhang J, Ge Y, Fu L and Wang Z: Downregulation of the GnT-V gene inhibits metastasis and invasion of BGC823 gastric cancer cells. Oncol Rep. 29:2392–2400. 2013.PubMed/NCBI
12	Seto K, Uchida F, Baba O, Yamatoji M, Karube R, Warabi E, Sakai S, Hasegawa S, Yamagata K, Yanagawa T, et al: Negative expression of N-acetylglucosaminyltransferase V in oral squamous cell carcinoma correlates with poor prognosis. Springerplus. 2:6572013. View Article : Google Scholar : PubMed/NCBI
13	Huang H, Chen W, Liu Q, Wei T, Zhu W, Meng H, Guo L and Zhang J: Inhibition of N-acetylglucosaminyltransferase V enhances sensitivity of radiotherapy in human prostate cancer. Biochem Biophys Res Commun. 451:345–351. 2014. View Article : Google Scholar : PubMed/NCBI
14	Guo HB, Liu F, Zhao JH and Chen HL: Down-regulation of N-acetylglucosaminyltransferase V by tumorigenesis- or metastasis-suppressor gene and its relation to metastatic potential of human hepatocarcinoma cells. J Cell Biochem. 79:370–385. 2000. View Article : Google Scholar : PubMed/NCBI
15	Taniguchi N, Ihara S, Saito T, Miyoshi E, Ikeda Y and Honke K: Implication of GnT-V in cancer metastasis: A glycomic approach for identification of a target protein and its unique function as an angiogenic cofactor. Glycoconj J. 18:859–865. 2001. View Article : Google Scholar
16	Yang JY, Luo HY, Lin QY, Liu ZM, Yan LN, Lin P, Zhang J and Lei S: Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R. World J Gastroenterol. 8:644–649. 2002. View Article : Google Scholar : PubMed/NCBI
17	Li GP, Chen XP and Ye L: The role of BCRP in hepatocellular carcinoma multidrug resistance and mechanism. J Abdom Surg. 5:242006.
18	Albermann N, Schmitz-Winnenthal FH, Z'graggen K, Volk C, Hoffmann MM, Haefeli WE and Weiss J: Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol. 70:949–958. 2005. View Article : Google Scholar : PubMed/NCBI
19	Yanagi M, Aoyagi Y, Suda T, Mita Y and Asakura H: N-Acetylglucosaminyltransferase V as a possible aid for the evaluation of tumor invasiveness in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 16:1282–1289. 2001. View Article : Google Scholar
20	Dosaka-Akita H, Miyoshi E, Suzuki O, Itoh T, Katoh H and Taniguchi N: Expression of N-acetylglucosaminyltransferase v is associated with prognosis and histology in non-small cell lung cancers. Clin Cancer Res. 10:1773–1779. 2004. View Article : Google Scholar : PubMed/NCBI
21	Guo P, Chen HJ, Wang QY and Chen HL: Down regulation of N-acetylglucosaminyltransferase V facilitates all-transretinoic acid to induce apoptosis of human hepatocarcinoma cells. Mol Cell Biochem. 284:103–110. 2006. View Article : Google Scholar : PubMed/NCBI
22	Miyoshi E, Terao M and Kamada Y: Physiological roles of N-ac etylglucosaminyltransferase V (GnT-V) in mice. BMB Rep. 45:554–559. 2012. View Article : Google Scholar : PubMed/NCBI
23	Nicholson DW: Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 6:1028–1042. 1999. View Article : Google Scholar : PubMed/NCBI
24	Beerheide W, Tan YJ, Teng E, Ting AE, Jedpiyawongse A and Srivatanakul P: Downregulation of proapoptotic proteins Bax and Bcl-X(S) in p53 overexpressing hepatocellular carcinomas. Biochem Biophys Res Commun. 273:54–61. 2000. View Article : Google Scholar : PubMed/NCBI
25	Deng B, Zhang XF, Zhu XC, Huang H, Jia HL, Ye QH, Dong QZ and Qin LX: Correlation and prognostic value of osteopontin and Bcl-2 in hepatocellular carcinoma patients after curative resection. Oncol Rep. 30:2795–2803. 2013.PubMed/NCBI
26	Stetler-Stevenson WG, Aznavoorian S and Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 9:541–573. 1993. View Article : Google Scholar : PubMed/NCBI
27	Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, et al: Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 7:2396–2404. 2001.PubMed/NCBI
28	Karahan N, Güney M, Baspinar S, Oral B, Kapucuoglu N and Mungan T: Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma. Eur J Gynaecol Oncol. 28:184–188. 2007.PubMed/NCBI
29	Määttä M, Soini Y, Liakka A and Autio-Harmainen H: Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: Implications for tumor progression and clinical prognosis. Clin Cancer Res. 6:2726–2734. 2000.PubMed/NCBI
30	Arii S, Mise M, Harada T, Furutani M, Ishigami S, Niwano M, Mizumoto M, Fukumoto M and Imamura M: Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology. 24:316–322. 1996. View Article : Google Scholar : PubMed/NCBI
31	Dean M, Hamon Y and Chimini G: The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res. 42:1007–1017. 2001.PubMed/NCBI
32	Gillet JP, Efferth T and Remacle J: Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta. 1775:237–262. 2007.PubMed/NCBI
33	Haimeur A, Conseil G, Deeley RG and Cole SP: The MRP-related and BCRP/ABCG2 multidrug resistance proteins: Biology, substrate specificity and regulation. Curr Drug Metab. 5:21–53. 2004. View Article : Google Scholar : PubMed/NCBI
34	Leslie EM, Deeley RG and Cole SP: Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 204:216–237. 2005. View Article : Google Scholar : PubMed/NCBI
35	Natarajan K, Xie Y, Baer MR and Ross DD: Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol. 83:1084–1103. 2012. View Article : Google Scholar : PubMed/NCBI
36	Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG and Schellens JH: Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 59:4559–4563. 1999.PubMed/NCBI
37	Robey RW, Medina-Pérez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD and Bates SE: Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res. 7:145–152. 2001.PubMed/NCBI
38	Duan Z, Brakora KA and Seiden MV: Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther. 3:833–838. 2004.PubMed/NCBI
39	Sukowati CH, Rosso N, Pascut D, Anfuso B, Torre G, Francalanci P, Crocè LS and Tiribelli C: Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma. BMC Gastroenterol. 12:1602012. View Article : Google Scholar : PubMed/NCBI